PT  - JOURNAL ARTICLE
AU  - Regine Kluge
AU  - Tim Wittig
AU  - Thomas W. Georgi
AU  - Lars Kurch
AU  - Osama Sabri
AU  - W. Hamish Wallace
AU  - Tomasz Klekawka
AU  - Ana Fernández-Teijeiro
AU  - Francesco Ceppi
AU  - Jonas Karlén
AU  - Jane Pears
AU  - Michaela Cepelová
AU  - Alexander Fosså
AU  - Auke Beishuizen
AU  - Lisa Lyngsie Hjalgrim
AU  - Dieter Körholz
AU  - Christine Mauz-Körholz
AU  - Dirk Hasenclever
TI  - Comparison of Interim PET Response to Second-Line Versus First-Line Treatment in Classic Hodgkin Lymphoma: Contribution to the Development of Response Criteria for Relapsed or Progressive Disease
AID  - 10.2967/jnumed.120.247924
DP  - 2021 Mar 01
TA  - Journal of Nuclear Medicine
PG  - 338--341
VI  - 62
IP  - 3
4099  - http://jnm.snmjournals.org/content/62/3/338.short
4100  - http://jnm.snmjournals.org/content/62/3/338.full
SO  - J Nucl Med2021 Mar 01; 62
AB  - In first-line treatment of Hodgkin lymphoma (HL), Deauville scores 1–3 define complete metabolic remission. Interim 18F-FDG PET is also used for relapse-treatment adaptation; however, PET response criteria are not validated for relapse treatment. Methods: We performed a pairwise comparative analysis of early response to first- and second-line treatments in 127 patients with classic HL who experienced relapse. The patients participated in the prospective, multicenter EuroNet-PHL-C1 study. Residual uptake was measured retrospectively using the qPET method, a validated semiautomatic quantitative extension of the Deauville score. Empiric cumulative distribution functions of the qPET values were used to systematically analyze the response to first- and second-line treatments. Results: Individual patients responded variably to first- and second-line treatments. However, the empiric cumulative distribution functions of the qPET values from all patients were nearly superimposable. Conclusion: The findings support that first- and second-line treatments in HL do not require different response criteria.